ABSTRACT
Bonnecor metabolism in the rat urine was studied. The main metabolites of bonnecor were identified by means of chromatography-mass-spectrometry.
Subject(s)
Anti-Arrhythmia Agents/urine , Dibenzazepines/urine , Animals , Anti-Arrhythmia Agents/pharmacokinetics , Biotransformation , Chemical Phenomena , Chemistry, Physical , Chromatography, Thin Layer , Dibenzazepines/pharmacokinetics , Gas Chromatography-Mass Spectrometry , RatsABSTRACT
The pharmacokinetics and pharmacodynamics of bonnecor were studied simultaneously in animals with experimental arrhythmia. It was shown that irrespective of the animal species and individual features of the drug elimination kinetics the level of bonnecor concentration correlated with the antiarrhythmic effect. The data on the excretion of bonnecor and its metabolites in the urine in the dog and man were obtained. The decrease of bioavailability at oral administration of bonnecor was demonstrated to be related to its intensive conversion in metabolite M-I.
Subject(s)
Anti-Arrhythmia Agents/pharmacokinetics , Dibenzazepines/pharmacokinetics , Animals , Anti-Arrhythmia Agents/analysis , Anti-Arrhythmia Agents/pharmacology , Anti-Arrhythmia Agents/therapeutic use , Biological Availability , Cardiac Complexes, Premature/drug therapy , Cardiac Complexes, Premature/metabolism , Cats , Dibenzazepines/analysis , Dibenzazepines/pharmacology , Dibenzazepines/therapeutic use , Dogs , Drug Evaluation , Drug Evaluation, Preclinical , Humans , Tachycardia/drug therapy , Tachycardia/metabolism , Time FactorsABSTRACT
The pharmacokinetics of befol at different routes of administration to animals and humans was studied. The therapeutic level of the drug concentration was established.
